NCT06607185 2026-03-13A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid TumorsEli Lilly and CompanyPhase 1 Active not recruiting750 enrolled
NCT04956640 2025-09-25Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)Eli Lilly and CompanyPhase 1/2 Recruiting540 enrolled
NCT00315861 2009-01-23Topotecan in Combination With Pemetrexed in Patients With Advanced MalignanciesSCRI Development Innovations, LLCPhase 1 Completed15 enrolled